Lifetime Brands, Inc. Reports First Quarter Financial Results
May 08, 2018 11:01 am UTC| Business
GARDEN CITY, N.Y., May 08, 2018 -- Lifetime Brands, Inc. (NasdaqGS:LCUT), a leading global provider of branded kitchenware, tableware and other products used in the home, today reported its financial results for the...
Shipt Adds Bi-Lo Grocery Delivery Across Southeast
May 08, 2018 11:01 am UTC| Business
BIRMINGHAM, Ala., May 08, 2018 -- Shipt, a leading online grocery marketplace, today announced that they will partner with BI-LO to bring grocery delivery to select metros across the states of Georgia, North Carolina...
Broadridge Reports Third Quarter and Nine Months Fiscal Year 2018 Results
May 08, 2018 11:01 am UTC| Business
Third Quarter Diluted EPS Growth of 43% and Adjusted EPS growth of 45% Total Revenues Rise 6% to $1.1 billion Recurring Revenues Increase 8% to $639 million Raising Fiscal Year 2018 EPS Guidance LAKE SUCCESS, N.Y.,...
OncoCyte to Report First Quarter 2018 Financial Results on May 15, 2018
May 08, 2018 11:01 am UTC| Business
ALAMEDA, Calif, May 08, 2018 -- OncoCyte Corporation (NYSE American:OCX), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, announced today that it will release its financial and...
RedHill Biopharma Reports First Quarter 2018 Financial Results
May 08, 2018 11:01 am UTC| Business
Key Highlights: Top-line results from Phase III study with RHB-104 for Crohn’s disease (MAP US study) expected in approximately 3 monthsTop-line results from confirmatory Phase III study with TALICIA® for H. pylori...
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP
May 08, 2018 11:01 am UTC| Business
- TransCon CNP is Company’s Third Product Candidate in Clinic - COPENHAGEN, Denmark, May 08, 2018 -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to...
Nabriva Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
May 08, 2018 11:01 am UTC| Business
- Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP 2) expected in Spring 2018 - - $90 million cash and investments as of March 31, 2018 expected to fund operations into the first quarter of 2020...